Video | Agriculture | Confidence | Economy | Energy | Employment | Finance | Media | Property | RBNZ | Science | SOEs | Tax | Technology | Telecoms | Tourism | Transport | Search

 

Manuka Health mulls capital raising options

Manuka Health mulls capital raising options after global launch of new honey products

By Fiona Rotherham


June 3 (BusinessDesk) - Manuka Health, the functional food and dietary supplement company, is reviewing capital-raising options to help fund a global roll-out of new products said to boost the antibacterial qualities of manuka honey and its pipeline of research and development.


The private company has ruled out a public listing at this stage but chief executive Kerry Paul said it was considering other options including new investors who bring more than just capital to the table.

Manuka Health was founded in 2006 and exports 90-plus products based on propolis, royal jelly, bee pollen, and manuka honey to 45 countries. It has annual turnover of more than $50 million, 80 staff, and is owned by a number of private shareholders including Paul and family interests associated with chairman Ray Thomson, and institutional investors, Milford Asset Management and Waterman Capital.

Manuka Health holds the worldwide licence and pays royalties on sales to Kobe University of Medicine in Japan for the new technology, which combines encapsulated manuka honey with plant-derived cyclodextrin, "creating a free-flowing powder that can easily be added to foods and beverages for ease of delivery of health benefits," according to a report on the company's website.

The combination boosts the anti-bacterial properties of the manuka honey by between 25 to 50 times depending on the product.

Manuka Health's products brand the technology as "CycloPower". Products using the technology are being rolled out worldwide, including capsules that support digestive health, chewable tablets for mouth and throat health, and a skincare range for problem skin.

The supplements can’t legally have therapeutic claims made about them. Paul said the company is funding a human clinical trial in New Zealand on the digestive tablets, that if successful on completion early next year, would allow it to register them to be sold with claimed health benefits.

“It gives the medical community more confidence in the product and we’d like to see these products used as complements to what else they’re prescribing. We’re not looking to replace traditional drug therapies,” Paul said.

Thomson said the company was “trading very strongly” and didn’t have to raise funds to complete the global rollout of CycloPower.

However, international expansion was expensive and the company had just funded a new $10 million, purpose-built honey processing and distribution centre in Te Awamatu last year which enabled it to triple production so “we’re evaluating a number of options in front of us”, he said.

Paul said the rollout of the CycloPower technology platform marked a turning point for the company.

“This is going to take us to a whole new level. My aim is to evolve this company from functional foods and supplements into a global natural healthcare company.”

Along with the CylcoPower technology, the company launched woundcare products last year sold through medical and pharmacy channels, a new skincare range this year, and has a number of other potential products in its R&D pipeline, Paul said.

Getting a new product from concept to commercialisation was one of the hardest management tasks, Paul said, although there was a global trend of ageing populations looking for natural health solutions that allow them to live better and for longer.

“We have to make sure we get the marketing positioning correct. We have to set it up so the consumers we’re targeting can see the benefits that will encourage them to buy.”

One of the other challenges was keeping focus on what products to prioritise, he said.

“You have to have a product that will have a unique selling proposition and can compete in world markets. Manuka honey has had a good spin but it has now become commoditised. Prices have become high and there is consumer resistance to paying those prices for manuka honey alone,” he said.

(BusinessDesk is funded by Callaghan Innovation to cover the commercialisation of innovation)

(BusinessDesk)

© Scoop Media

 
 
 
Business Headlines | Sci-Tech Headlines

 

Stats NZ: Consents For New Homes At All-Time High

A record 41,028 new homes have been consented in the year ended March 2021, Stats NZ said today. The previous record for the annual number of new homes consented was 40,025 in the year ended February 1974. “Within 10 years the number of new homes ... More>>

Stats NZ: Unemployment Declines As Underutilisation Rises

The seasonally adjusted unemployment rate decreased to 4.7 percent in the March 2021 quarter, continuing to fall from its recent peak of 5.2 percent in the September 2020 quarter but remaining high compared with recent years, Stats NZ said today. ... More>>

ALSO:

Digitl: The Story Behind Vodafone’s FibreX Court Ruling

Vodafone’s FibreX service was in the news this week. What is the story behind the Fair Trading Act court case? More>>

Reserve Bank: Concerned About New Zealand's Rising House Prices

New Zealand house prices have risen significantly in the past 12 months. This has raised concerns at the Reserve Bank of New Zealand – Te Putea Matua about the risk this poses to financial stability. Central banks responded swiftly to the global ... More>>

Westpac: Announces Strong Financial Result

Westpac New Zealand (Westpac NZ) [i] says a strong half-year financial result has been driven by better than expected economic conditions. Chief Executive David McLean said while the global COVID-19 pandemic was far from over, the financial effect on ... More>>

MYOB: SME Confidence In Economic Performance Still Cautious

New insights from the annual MYOB Business Monitor have shown the SME sector is still cautious about the potential for further economic recovery, with two-in-five (41%) expecting the New Zealand economy to decline this year. The latest research ... More>>